1 / 10

Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the

Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the Anesthetic and Life Support Drugs Advisory Committee. ARCOS (sales at the retail level). Year-End Reports (distributions by dosage form manufacturers). IMS Health, IMS National Sales Perspectives ™

kaipo
Download Presentation

Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presented by Terance Woodworth, M.S. at the September 9, 2003 meeting of the Anesthetic and Life Support Drugs Advisory Committee

  2. ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 Aggregate Production Quotas Estimates of U.S. ConsumptionMorphine (sale) (Kg)

  3. Estimates of U.S. ConsumptionHydrocodone (sale) ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) (Kg) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 Aggregate Production Quotas

  4. ARCOS (sales at the retail level) Year-End Reports (distributions by dosage form manufacturers) IMS Health, IMS National Sales Perspectives™ Extracted August 2003 ( total kg dispensed) Aggregate Production Quotas Estimates of U.S. ConsumptionOxycodone (sale) (Kg)

  5. DAWN Mentions per 100,000 scripts Drug Abuse Warning Network IMS Health, National Prescription Audit Plus™ Consequences of Increased AvailabilityMorphine 1500 1200 900 (DAWN Emergency Department Mentions) Total Prescriptions Dispensed (per 100,000 pop.) 600 300 0

  6. 40,000 32,000 24,000 Total Prescriptions Dispensed (per 100,000 pop.) 16,000 8,000 0 DAWN Mentions per 100,000 scripts Drug Abuse Warning Network IMS Health, National Prescription Audit Plus™ Consequences of Increased AvailabilityHydrocodone (DAWN Emergency Department Mentions)

  7. DAWN Mentions per 100,000 scripts Drug Abuse Warning Network IMS Health, National Prescription Audit Plus™ Consequences of Increased Availability Oxycodone 15,000 12,000 9,000 (DAWN Emergency Department Mentions) Total Prescriptions Dispensed (per 100,000 pop.) 6,000 3,000 0

  8. DAWN Mentions per 100,000 scripts Linear Regression Trend line Attachment G Consequences of Increased Availability Morphine Hydrocodone Oxycodone

  9. Attachment H State and Local Seizures of Opioids Source: National Forensic Laboratory Information System (NFLIS) 2001 2002 2000 2003 * *As of 8/27/03

  10. Promotional Expenditures vs Dollar Sales IMS IPS and NSP Audits* $1,800,000 2002 Total Promotional Dollars $1,600,000 2002 Total Dollars Sales NSP $1,400,000 $1,200,000 $1,000,000 Dollars in Thousands $800,000 $600,000 $400,000 $200,000 $0 Actiq Avinza Kadian Duragesic MSContin OxyContin *IMS Health, IMS National Sales Perspectives™, Extracted August 2003 IMS Health, Integrated Promotional Services Audit™, Extracted August 2003

More Related